Learn More About the 8th TIL Therapies Summit
The 8th TIL Therapies Summit brings together the companies, researchers, and clinical leaders driving the next generation of tumor-infiltrating lymphocyte therapies for solid tumors. Explore the articles below to gain insight into the latest advances in engineered TIL, gene editing, manufacturing innovation, potency and quality control frameworks, clinical development, and commercialization strategies, alongside the regulatory, operational, and scalability challenges shaping the field. These are the discussions helping determine how TIL therapies can expand patient access, improve outcomes across solid tumor indications, and evolve from promising clinical programs into commercially successful treatments.
Browse our selection of expert insights exploring the latest advances, challenges, and opportunities shaping the future of TIL therapies.
The Future of TIL Therapy Beyond Melanoma
Explore the opportunities and challenges of expanding TIL therapies beyond melanoma, and discover how developers are advancing engineered TILs, manufacturing innovation, and combination strategies to unlock success across solid tumors.
The Biggest Manufacturing Challenges Facing TIL Developers
Explore the manufacturing challenges impacting TIL development, and discover how developers are improving consistency, scalability, and turnaround times to support commercial success.
How Are Companies Improving TIL Persistence and Durability?
Explore the strategies being used to enhance TIL persistence and durability, and discover how developers are leveraging cell selection, gene editing, and combination approaches to drive long-term clinical responses.
What Can the Industry Learn from the First Approved TIL Therapies?
Explore the lessons emerging from the first approved TIL therapies, and discover how manufacturing readiness, treatment logistics, and commercial execution are shaping the future of the field.